ストックスクリーナーアプリを入手
4.28
3.17%
-0.14
プレマーケット:
4.30
0.02
+0.47%
前日終値:
$4.42
開ける：
$4.4
24時間の取引高:
620.46K
Relative Volume:
1.31
時価総額：
$389.14M
収益：
$35.11M
当期純損益:
$-79.20M
株価収益率:
-0.9869
EPS:
-4.3367
ネットキャッシュフロー:
$-88.62M
1週間 パフォーマンス:
+3.38%
1か月 パフォーマンス:
+5.16%
6か月 パフォーマンス:
+38.51%
1年 パフォーマンス:
-29.13%
1日の値動き範囲:
$4.24
$4.66
1週間の範囲:
$4.115
$4.66
52週間の値動き範囲:
$1.35
$6.63
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.28 | 379.14M | 35.11M | -79.20M | -88.62M | -4.3367 |
VRTX
Vertex Pharmaceuticals Inc
|
435.10 | 110.67B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
766.02 | 80.98B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
787.95 | 49.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.79 | 41.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.81 | 33.28B | 5.36B | 287.73M | 924.18M | 2.5229 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-09 | 開始されました | Guggenheim | Buy |
| 2025-12-05 | 再開されました | Stifel | Buy |
| 2023-12-12 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 再開されました | B. Riley Securities | Buy |
| 2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | ROTH Capital | Buy |
| 2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
| 2019-12-05 | 開始されました | B. Riley FBR | Buy |
| 2019-06-07 | 開始されました | Stifel | Buy |
| 2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
ROKU (Roku Inc.) tops Q4 2025 EPS estimates by a wide margin, shares rise nearly 4 percent in today’s session.Trending Stock Ideas - Xã Thanh Hà
Is X4 Pharmaceuticals (XFOR) stock a solid choice for investors | Q4 2025: Earnings Beat Estimates - Cổng thông tin điện tử tỉnh Lào Cai
Liquidia Corp.: Prime Candidate For A Takeout By Large Pharma (LQDA) - Seeking Alpha
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in Q1? - TradingView
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target? - TradingView
Layoff Tracker: BMS layoffs hits Lawrenceville hard, adding 200+ to cut count - BioSpace
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results for Azetukalner in Focal Onset Seizures at AAN 2026 - Quiver Quantitative
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results - GlobeNewswire
X4 Pharmaceuticals (XFOR) Stock: Next Quarter (Institutional Demand) 2026-04-18Crowd Entry Points - Cổng thông tin điện tử tỉnh Lào Cai
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Ionis (NASDAQ: IONS) director sells 5,000 shares under Rule 10b5-1 plan - Stock Titan
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Insider Sell: How correlated is X4 Pharmaceuticals Inc to the S P5002026 Breakouts & Breakdowns & Weekly High Potential Alerts - baoquankhu1.vn
EPS Watch: How does X4 Pharmaceuticals Inc score in quality rankings2026 Outlook & Risk Managed Investment Strategies - baoquankhu1.vn
Aug Setups: What is the long term forecast for X4 Pharmaceuticals Inc stock - baoquankhu1.vn
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside - TradingView — Track All Markets
Setup Watch: Is X4 Pharmaceuticals Inc stock a value trapQuarterly Performance Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
Leading Companies Reinforcing Their Presence in the C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market - openPR.com
Director at Adial (NASDAQ: ADIL) receives 9,185 restricted shares - Stock Titan
One X4 Pharmaceuticals Insider Raised Their Stake In The Previous Year - Yahoo Finance
Commentary: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people - Los Angeles Times
Weekly Trades: Is X4 Pharmaceuticals Inc stock a value trapQuarterly Trade Review & Reliable Price Breakout Alerts - baoquankhu1.vn
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - PR Newswire
Meme Stocks: Is X4 Pharmaceuticals Inc a momentum stock2026 Intraday Action & Stepwise Swing Trade Plans - baoquankhu1.vn
Recursion (NASDAQ: RXRX) director sale under Rule 10b5-1 trading plan - Stock Titan
Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight - Barchart
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for - GlobeNewswire
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors - TMX Newsfile
Aug Selloffs: How correlated is X4 Pharmaceuticals Inc to the S P5002026 Stock Rankings & Fast Entry Momentum Alerts - baoquankhu1.vn
Neurocrine bets nearly $3bn on deal for insatiable hunger treatment - Financial Times
XFOR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
XFOR SEC FilingsX4 Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Small Rule 10b5-1 sale by Regeneron (REGN) director Arthur F. Ryan - Stock Titan
Kiora (KPRX) CEO withholds 1,906 shares to cover stock taxes - Stock Titan
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
XFOR Stock Analysis: X4 Pharmaceuticals Inc. gains 5.33 percent to trade at 4.35 - Cổng thông tin điện tử Tỉnh Sơn La
Stonepine Capital (QNRX) files Form 4 as 10% owner with no trades - Stock Titan
Is ANIP Undervalued? How to Read Its 9.3x Forward P/E - TradingView
Tech Rally: What analysts say about X4 Pharmaceuticals Inc stock2026 Buyback Activity & Safe Capital Investment Plans - baoquankhu1.vn
Is X4 Pharmaceuticals Inc impacted by rising ratesWeekly Earnings Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Performance Recap: How does X4 Pharmaceuticals Inc score in quality rankings2026 PreEarnings & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Venrock funds trim KalVista (KALV) stake, retain 5.09M shares - Stock Titan
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Global X Japan Co. Ltd. - MarketBeat
Earnings Risk: How correlated is X4 Pharmaceuticals Inc to the S P5002026 Investor Takeaways & Fast Gain Swing Alerts - baoquankhu1.vn
XFOR|X4 Pharmaceuticals Inc|Price:4.090|Chg%:0.27 - TradingKey
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) - Business Wire
Tarsus Pharmaceuticals (TARS) COO sells 2,989 shares in planned trade - Stock Titan
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong - WHEC.com
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review - Business Wire
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
X 4 Pharmaceuticals Inc (XFOR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
4.95%
大文字化:
|
ボリューム (24 時間):